key: cord-0898833-artp54tn
authors: Frohman, Elliot M.; Melamed, Esther; Cruz, Roberto Alejandro; Longmuir, Reid; Steinman, Lawrence; Zamvil, Scott S.; Villemarette-Pittman, Nicole R.; Frohman, Teresa C.; Parsons, Matthew S.
title: Part I. SARS-CoV-2 triggered ‘PANIC’ attack in severe COVID-19()
date: 2020-05-21
journal: J Neurol Sci
DOI: 10.1016/j.jns.2020.116936
sha: fe6e0bae7cbdcd638387069c292a4d8133b8dfa6
doc_id: 898833
cord_uid: artp54tn

The COVID-19 pandemic has produced a world-wide collapse of social and economic infrastructure, as well as constraining our freedom of movement. This respiratory tract infection is unprecedented in that it targets the most distal and highly vulnerable aspect of the human bronchopulmonary tree, specifically, the alveoli that are responsible for the loading of oxygen upon red cell hemoglobin for use by all of the body's tissues. In most symptomatic individuals, the reaction is a productive and mild immune-mediated syndrome, with limited damage to the lung tissues. About 20% of those affected experience a virus capable of producing what can only be described as a cataclysmic set of immune activation responses that can culminate in the diffuse and irreversible obliteration of the distal alveoli, that then leads to a virtual collapse of the gas-exchange apparatus. Here, in Part I of a duology on the characterization and potential treatment for COVID-19, we define severe COVID-19 as a consequence of the SARS-CoV-2 virus' ability to trigger what we now designate for the first time, as a ‘Prolific Activation of a Network-Immune-Inflammatory Crisis’, or ‘PANIC’ Attack, in the alveolar tree. In Part II we describe an immunotherapeutic hypothesis worthy of the organization of a randomized clinical trial in order to ascertain whether a repurposed, generic, inexpensive, and widely available agent is capable of abolishing ‘PANIC’; thereby preventing or mitigating severe COVID-19, with monumental ramifications for world health, and the global pandemic that continues to threaten it.

solitary tract and nucleus localized to the caudal medullary tegementum. The integrity of the complex connectivity of this circuitry must be maintained in order to achieve its goal of regulating all functions of the respiratory system to maintain oxygen saturation and delivery to ensure continuous organ tissue viability.

A principal goal herein is to confirm both face and construct validity for the principle of this new definition for a poorly coordinated and dysregulated sequence of coincidentally activated limbs of the immune network (i.e. PANIC), and the consequences of such upon the primary target tissue for an infection as virulent and strategically ominous as the SARS-CoV-2 agent. Further, given the prolific immune activation associated with microbial-induced 'PANIC', in Part II of this publication, we advance the hypothesis that effective therapy should thereby provide a pleiotropic strategy commensurate with the range of the immune system's diversity of activation by the SARS-CoV-2 virus.

The SARS-CoV-2 agent triggers PANIC which the authors find reminiscent of phenomenonlogy which we have previously identified (and published in the Journal of the transmissibility of SARS-CoV-2, in conjunction with the large proportion of both mildly affected and asymptomatic individuals harboring infection, both 'shelter in place', together with widespread availability of testing to confirm infection, as well as active immunity, represents our best strategy to prevent further dissemination and also to identify newly infected cases as early as possible.

According to currently available data, at the time of submission of this article, approximately 80% of individuals who become infected with SARS-CoV-2 will experience a relatively mild, short duration syndrome; with many being wholly asymptomatic. The other 20% of SARS-CoV-2 infected patients will progress to exhibit a severe variant of this infection characterized by fever and a respiratory tract 'flu-like' illness. They may suffer from fever, cough, pharyngitis, headache, dyspnea, myalgias, chest pain, nausea, vomiting, confusion, and interestingly, anosmia and dysgeusia in a small albeit conspicuous proportion of patients (~5%) [9] [10] [11] . This severe disease transitions to an accelerated course of predominant respiratory deterioration, requiring intensive multidisciplinary management, including respiratory support with pressure ventilation. Addtionally, there is a high predilection for a diverse constellation multi-organ derangements, with the most severely affected individuals exhibiting multi-organ failure [2] .

In the initial Wuwan cohort, characteristic chest CT findings were identified in 98% of 41 patients, with involvement of both lungs, and features consistent with the 'so-called' ground glass opacifications. Of those patients that deteriorated, most required intensive care unit (ICU) management, while paradoxically exhibiting a resolution of lung consolidations in comparison to those not requiring admission to the ICU [2] . The median duration (in days) between the onset of symptoms and the passing of clinically relevant and prognostic milestones of the severely affected was also documented in the Wuhan patients. Specifically, admission to hospital (7 days), onset of dyspnea (8 days), diagnosis of ARDS (9 days), admission to ICU (10.5 days), and mechanical ventilation (10.5 days). The timing from hospital admission to diagnosis of ARDS was also reported to be as short as two days, at which point such patients had a mortality rate of 15% [2] .

Risk factors associated with the designation of severe COVID-19 disease included male gender, advanced age, and pre-existing co-morbid conditions, especially hypertension, diabetes, morbid obesity, and smoking [2] . The clinical semiology for the most severly affected patients was most commonly comprised of interstitial pneumonia with rapid transition to ARDS, septic shock, and evidence of the liberation of acute phase reactants in conjunction with macrophage activation. Additionally, serum elevation of C-reactive protein (CRP) and D-dimer, were correlated with liver dysfunction and hyperferritinemia, laboratory findings which can be accompanied by the syndrome of disseminated intravascular coagulation (DIC) [2] .

In the severely ill COVID-19 patients, front-line healthcare workers have been largely preoccupied with providing adequate life-support, prioritizing the integrity of the circulatory system, and keeping blood oxygen saturation above the threshold where end organ damage ensues. In those with a rapid transition from minor symptoms to urgent admission to an ICU, the majority will require ventilator support, along with continuous observation and repeated assessments of each of the major body systems. Given the potential for any given COVID-19

patient to abruptly deteriorate, clinical management mandates a systematic sequence of intensive care measures and protocols principally aimed at avoiding a period of hypoxic J o u r n a l P r e -p r o o f Journal Pre-proof ischemia. It is for this reason, at least in part, that our understanding of the neurologic manifestations of COVID-19 lags behind our understanding of the more omnipresent and existential concerns that are associated with patients so severely affected by this infection.

The ICU priorities can hinder the ability of any subspecialist to carry out their assessments, as well as limit recommendations for those investigations that require the patient to leave the ICU setting (e.g. as with the performance of imaging studies including CT and MRI). Each departure for additional testing must be cautiously weighed against the risks and benefits of such investigations. Despite these limitations, we have now gained some insights into complications of the SARS-CoV-2 infection that target the CNS and peripheral nervous system (PNS) [12] [13] [14] [15] [16] [17] [18] [19] .

actions of SARS-CoV-2 on the CNS and PNS. Indirect actions of the virus are related to injury to peripheral organs, such as the lungs, kidneys, liver, and heart. For example, myocardial and lung invasion by SARS-CoV-2 could result in cardiac failure and arrhythmias, which could in turn increase the secondary risk of stroke [20] [21] [22] [23] . Alternatively, SARS-CoV-2 could directly damage the brain and spinal cord either via hematogenous spread or via neural propagation into the CNS [24] .

Other coronaviruses, such as SARS-CoV1 and HCoV-OC43 have been shown to enter into the nasal passages and spread to the olfactory bulb, pyriform cortex, dorsal nucleus of the rafe in the brainstem, and spinal cord [25, 26] . Of note, ablation within the olfactory pathway can prevent the neural spread of MHV coronavirus in animals [27] . Cellular entry is thought to occur through the angiotensin-converting enzyme 2 receptor (ACE2R). Interestingly, ACE2R is J o u r n a l P r e -p r o o f Journal Pre-proof expressed widely in the CNS within neurons, motor cortex, hypothalamus, thalamus, and brainstem [28] [29] [30] [31] [32] [33] .

The physical distribution of ACE2R in the brain could account for some of the clinical symptoms observed in patients. For example, direct neuronal injury within the brainstem cardiorespiratory centers in the medulla, could explain the peak disease cardiovascular and respiratory complications in COVID-19 patients [25] . In addition, anosmia and ageusia in COVID-19 patients may be related to viral entry through ACE2R within the olfactory system or within the hypothalamus.

A recently published retrospective observational case series focused upon the neurologic manifestations of COVID-19 from Wuhan China, and included 214 consecutive hospitalized patients with laboratory-confirmed diagnosis [10] . This analysis showed that approximately 60% of patients were designated as having mild disease, with the remainder characterized as having severe infection, defined with respect to their respiratory status.

Approximately 36% of the cohort exhibited neurological manifestations, with those designated as having more severe disease being more likely to significantly harbor comorbid conditions with hypertension being most common, as well as being significantly less likely to present with the more typical respiratory symptoms (at least at presentation) of COVID-19, such as cough in the context of fever [10] . alveolar membrane is 1-cell-thick and necessitates an intimate and tight juxtaposition of the alveolar epithelium with that of the pulmonary capillary endothelium, also with the thickness of a single cell. The single-cell arrangement, and ultra-tight juxtaposition of the capillary anatomy with that of the alveolar epithelium, constitutes an ideal architecture for the principal goal of pulmonary physiology, the loading of oxygen onto red cell hemoglobin and the expulsion of CO 2 from the lungs into the ambient air [ Figure 3 ]. 

High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

WHO. Novel coronavirus -Japan (ex-China)

First travel-related case of 2019 novel coronavirus detected in United States

A novel coronavirus genome identified in a cluster of pneumonia cases -Wuhan

A new threat from an old enemy: Re-emergence of coronavirus (Review)

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurological Insights of COVID-19 Pandemic

Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019-2020

Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurological manifestations in COVID-19 caused by SARS-CoV-2

Neurologic complications of coronavirus infections

Emergency Room Neurology in times of COVID-19: Malignant Ischemic Stroke and SARS-COV2 Infection

Neurological complications of coronavirus and COVID-19

Challenges and Potential Solutions of Stroke Care During the Coronavirus Disease

Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain

Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain reninangiotensin system

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients

The microanatomy of the alveolar duct system

Airway hygiene in the intensive care unit

Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients?

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Tian, Dysregulation of immune re sponse in patients with COVID-19 in Wuhan, China

A pathological report of three COVID-19 cases by minimally invasive autopsies

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio

Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? Circulation

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis

C4a: the third anaphylatoxin of the human complement system

Complement system part I-molecular mechanisms of activation and regulation

Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross

Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from

Role of C5a in inflammatory responses

The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses

Analysis of serum cytokines in patients with severe acute respiratory syndrome

Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections

Severe Acute Respiratory Syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate sars pathogenesis by modulating intrinsic functions of monocytederived macrophages and dendritic cells

Immunological responses against SARS-coronavirus infection in humans

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), medRxiv

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Middle East Respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARSlike disease

Distinct immune response in two MERSCoVinfected patients: Can we go from bench to bedside?

The authors wish to express our gratitude to our medical illustrator, Mr. Jason Ooi, for his evidence-based and hypothetical renditions of the putative pathobiological underpinnings of the SARS-CoV-2 induced 'Prolific Activation of a Network Immune-Mediated Inflammatory